{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:21Z","timestamp":1753891821696,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Light chain deposition disease (LCDD) is a clonal plasma cell disorder characterized by the deposition of nonamyloid monoclonal light chains in multiple organs. It can affect various systems throughout the body, mainly the kidneys. Symptoms may include renal insufficiency, proteinuria, hematuria, and others. Due to the lack of effective treatment, LCDD patients with kidney involvement often progress to chronic kidney failure, ultimately requiring renal replacement therapy. Daratumumab, an anti-CD38 monoclonal antibody, is primarily used for the treatment of relapsed and refractory multiple myeloma. Recent studies have shown that daratumumab also has an encouraging effect on light-chain amyloidosis. Here, we report the case of an LCDD (\u03ba chain) patient with proteinuria, renal insufficiency, and anemia who was followed up for 3 years, during which he received daratumumab treatment. After the daratumumab treatment, the hematologic response continued progressing to a complete response without any adverse effects and continuous renal function improvement at a low serum free light chain (sFLC) level. This case shows that daratumumab is effective at treating LCDD. For LCDD patients with kidney involvement, frequent monitoring and active control of free light chain levels are necessary, as reaching the lowest sFLC of &amp;lt; 20 mg\/L may help to improve kidney function.<\/jats:p>","DOI":"10.3389\/fonc.2025.1466323","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:22:53Z","timestamp":1738218173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Xueying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.08.040","article-title":"Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors","volume":"42","author":"Pozzi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12967-019-02147-4","article-title":"The pathogenesis of renal injury and treatment in light chain deposition disease","volume":"17","author":"Wang","year":"2019","journal-title":"J Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu045","article-title":"Light chain deposition disease without glomerular proteinuria: A diagnostic challenge for the nephrologist","volume":"29","author":"Sicard","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.4994","article-title":"Light-chain deposition disease successfully treated with bortezomib in an elderly patient: A case report and review of the literature","volume":"54","author":"Wada","year":"2015","journal-title":"Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13548","article-title":"Treatment of light chain deposition disease with bortezomib and dexamethasone","volume":"94","author":"Kastritis","year":"2009","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.619610","article-title":"Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement","volume":"53","author":"Minarik","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5935\/0101-2800.20160071","article-title":"Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone","volume":"38","author":"Souto Filho","year":"2016","journal-title":"J Bras Nefrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14740\/jh1038","article-title":"Treatment of light chain deposition disease: A systematic review","volume":"11","author":"Masood","year":"2022","journal-title":"J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705447","article-title":"Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation","volume":"38","author":"Weichman","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01821.x","article-title":"Bortezomib\/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease","volume":"89","author":"Tovar","year":"2012","journal-title":"Eur J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease","volume":"23","author":"Lorenz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.1971192","article-title":"Consolidation with a short course of daratumumab in patients with al amyloidosis or light chain deposition disease","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010645","article-title":"Innovative anti-cd38 and anti-bcma targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030545","article-title":"Daratumumab in the treatment of light-chain (Al) amyloidosis","volume":"10","author":"Palladini","year":"2021","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001553","article-title":"Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function","volume":"4","author":"Milani","year":"2020","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0258-y","article-title":"Optimizing deep response assessment for al amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26025","article-title":"Involved free light chains <10 mg\/L with treatment predict better outcomes in systemic light-chain amyloidosis","volume":"96","author":"Godara","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1466323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:22:55Z","timestamp":1738218175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1466323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1466323"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1466323","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"article-number":"1466323"}}